loader image

What to Trade on Top of Pfizer’s COVID-19 Pill News

by | Nov 5, 2021 | Stocks

On Friday morning, huge news hit the market: jobs numbers and Pfizer’s new COVID-19 pill…

Nonfarm payrolls increased by 531,000 — the biggest number since July — and the unemployment rate shrank to 4.6%. 

This beat expectations and is a great sign that the economy is ramping up.

Another key role in the economy roaring back to life is Pfizer’s game-changing news about its experimental COVID-19 pill. The company said its pill cuts the risk of death or hospitalization by 89%.

Shares of the company surged Friday morning — up nearly 10% before coming back down some.

If what Pfizer is saying is true and this pill is approved by the FDA, we’re looking at what could be the end of the COVID-19 era.

But to me, what’s even crazier about Pfizer’s COVID-19 pill news is that I sent out a free trade that urged traders to get into the stock two days before the news hit.

As a matter of fact, I’ve been talking about the company since Monday

Trading the Pfizer COVID-19 Pill News Before It Hit the Market

On Monday, I told traders to keep an eye out on the earnings report for Pfizer Inc. (NYSE: PFE).

The market was looking for Pfizer to boost 2021 guidance on the back of COVID-19 vaccine sales. What I found more interesting was the company’s guidance on 2022 estimates for the vaccine. 

Production was ramping up, and the demand for it in middle-income countries — as well as the possible boost in the younger demographic in the U.S. — could create upside. 

The stock was expected to move 4.5% the day after earnings… which is about double the normal post-earnings move for PFE. And boy, the stock did not disappoint.

I even went so far as sending out a bullish free trade idea on Wednesday morning to get in on the stock, as I expected to see some major upside from a technical standpoint. It had just come off of a great earnings report and the risk versus reward was worth biting to me.

I had no idea that Pfizer would come out with what people are dubbing “the cure for COVID-19” just days later.

However, the traders that did listen to me made bank within a day. If you were one of them, let me know how the trade went at jeff@joyofthetrade.com! 

Luckily, that’s not the only stock on my radar that’s been hitting a home run lately — and the next one happens to be one of my Money Flow Elite trades for November.

Check out the video below to learn more about how to trade Pfizer’s COVID-19 pill news, and my Money Flow Elite pick that’s skyrocketing.

Send any trading questions to jeff@joyofthetrade.com and stay ahead of the markets, especially these choppy ones, by subscribing to our YouTube channel

WRITTEN BY<br>Jeff Zananiri

Jeff Zananiri

What to read next

99 Problems and a “Pivot” is One

99 Problems and a “Pivot” is One

A friend of mine sent me this chart about three months ago. I should probably print it and keep it in my wallet next to a photo of my daughter. Given the sheer number of questions I’ve fielded lately, I’ll probably end up showing this chart more than her picture.

read more
Everything Everywhere, Going Down, All At Once

Everything Everywhere, Going Down, All At Once

When our momentum reading went negative last week, I didn’t know that we’d have the second largest bank failure in U.S. history three days later. All I knew was that it went negative… and that we got out of the way.

read more
Trust But Verify…

Trust But Verify…

I want to talk about our version of “Trust but Verify” in the markets. Qualification is the most important part of the investing process. And this F score value strategy looks to be crushing the current market.

read more

Have any questions? Contact Our Customer Service Team